Member Info for Noise

Ratcliffe, for a while basically Winnifrith was in charge of organising AIM exhibitors at the investor show exhibition. Some would say he often bullied cos, cause he was often mean to AIM cos but would then miraculously start being nice to them when they paid their fees to attend the show. I think there were a few mining companies that complained about him doing that. No idea why he bothered Valirx in particular but they was 2-3 years ago.

From recollection Valirx had lent Valiseek a moderate sum (£0.5-2m?) and part of the deal was at minimum to repay the Valirx loan...so fingers crossed for that in the short to medium term.

Well.... Blimey.

Colour me impressed, assume more details to follow.

There was a declared intent from Valiseek to partner or IPO around 1.5 years ago, I recall Suzy did an investors evening night where they wanted cash to tide them through to the partner/IPO.

I don't recall a Nasdaq listing being mentioned, but hey, I'd prefer that to the broker nonsense of the AIM market.

Phase 1a Single Dose Safety study
Phase 1b Multiple dose study, safety and pharmacokinetics
Phase 2a Usually pilot studies designed to demonstrate clinical efficacy or biological activity ('proof of concept')
Phase 2b Optimum dose at which the drug shows biological activity with minimal side-effects

We sorta have the efficacy/proof of concept, from the first cohorts published so far, I think there's only been 1-2 non-responders. So far everything from 4mg dosing upwards seems to have either stopped tumour growth or massively reduced it (in PSA terms).

Difficult to judge what new content is in this RNS

"An interim inspection of the trial's output indicates that the compound is and continues to perform as predicted from the pre-clinical findings."

OK...well the trial hasn't been stopped so it must be vaguely doing what it says on the tin, and besides the high-blood pressure incident in the guy with high-blood pressure, it seems to remain safe.

Pre-clinical data pretty much said all prostate cancer growth was stopped, although this seems to further indicate this may kill off the metastasised/misbehaving tumours, since the PSA data says 40-50% tumour reduction.

It seems UCLH have reported their regular 3 monthly update to Valirx, that fits with historic comments with how UCLH report.

Not really sure what this means. Does it mean considering offers already, or just airy fairy thinking about it? "The board is currently evaluating the optimum strategies for adding value during the study and commercialising the compound. The Company will keep shareholders and stakeholders informed of progress."

Cereus, RNS announced director buys (5.3m shares) on 31st December 2018.

abacus, I would say we are currently stuck in a 250p (min) and 300p (max) channel, you can see the price rebounding everytime it hits 250p, bouncing back down everytime at around 300p. Quite nice to trade if you have the balls for it. Seems heavily driven by sentiment

Stach, there was a giant rise after the end of the VAL401 trial, and frankly I always considered 201 the big ticket, so I am hopeful we are not far away from a large rise based on sentiment/timing alone.

Last January, I think we went from 0.95 to 7p in a week at the end of the 401 trial, I think the newsflow potential of that repeating is certainly possible. Throw in the wildcard that is 401 and who knows.

I have to admit I'll probably review my exit strategy in the next 6 months.

Isleworth (London) is not the largest place, it's a decent commuter hop into London from there though, some decent curry in Southall/Hounslow and a decent nightlife (with unrespectable oiks like myself) down in Kew Bridge!

Scooby, I find it entertaining to know that I am officially ramper #34 for Valirx!

October 17th 2018 "The current cohort has already received the escalated dose. This marks the point that VAL201 entered the concluding stages of the Phase l/ll clinical trial"

The trial is a 18-26 week trial, today marks the end of 21 weeks, so the first (and final Valirx..?) cohort have probably just started to complete their treatment.

There should actually be some news to report in the next 2-4 weeks.

Ha

Shorting is an odd environment, but frankly on AIM it is not the core problem.

On larger stocks shorting can be a bit insider, with the specialist/rumour mill brigade coupling with a self-fulfilling prophecy as the larger hedge funds spread bad vibes/leak stories to the press/send weevils to flood the bulletin boards.

Does anybody know the background and future effects of the government's life science sector deal that Satu spoke about?

I can see some names being banded about, some generic waffle, personalised medicines and genetic screening/therapies. Autolus, Oxford Biomedica and Roslin Cell therapies, GW Pharmaceuticals, Eli Lilly getting involved.

--500,000 whole genomes being sequenced through the NHS Genomic Medicine Service by 2024

It would be hellish nice if we could partner someone with the cash to turn our relatively slow progress of VAL101 etc. into the labs. Admittedly I know why 101 has taken so long (it is pseudo-genetic engineering, a complicated ethical environment) but it still seems 12-24 months away from patients.

Could you imagine the activity if someone walked in with £200m and an army of medics who could turn VAL201/301/101 into a multi-centre trial for 10+ health conditions?

Yeah I'm not really too sure what to expect on VAL401, if a deal is going to happen (50-70% probability? it's low risk, low cost, but with wide user potential on most adenocarcinomas), it should be happening in the next 1-6 months, but what it will be no one knows.

It's a slightly curious drug in the sense of a phase 3 reformulation, would a £10-20m upfront deal be realistic? For some reason I suspect if the deal comes it will be with a small to midcap pharma, probably not a household name.

I don't really know how they would structure the deal, whether they partner into an IPO etc. I'd quite like to retain some ownership or future % revenue from it, but if it allows Valirx to develop 201, 301 and 101 I'd be very happy to see 401 leave us for a briefcase full of 500 euro notes!!

By my calculations the escalated dose cohort probably began dosing around 10th October 2018 on a 5 month trial basis, we are now at 4.9 months and you could suggest an update (minor or major?) was due in the following 4-6 weeks.

We had a pretty decent spike when the 401 trial completed, I wonder if that could be replicated for the 201 trial?

Some interesting UK biotech news this morning, Nightstar (phase 3 gene therapy for vision-related genetic disorders) sold for $800m. Hope they'll keep the UK HQ down by Tottenham Court Road.

Christ, I haven't been here that long and I think we've gone from 30m shares to 680m

Oh well, least it's "only" 80m shares.

ololololololo